CD19 specific CAR T cell therapy / Baylor Scott & White Research Institute  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD19 specific CAR T cell therapy / Baylor Scott & White Research Institute
ANCHOR, NCT00840853: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

Active, not recruiting
1
68
US
CD19CAR/virus specific T cells, Benadryl and Tylenol, Diphenhydramine and acetaminophen
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
04/16
04/31
ANCHOR, NCT03774654: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies

Recruiting
1
48
US
CD19.CAR-aNKT cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
04/25
03/35
SAGAN, NCT01853631: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL

Recruiting
1
64
US
Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
12/24
02/36

Download Options